GlassScriptPhysician profile
Sadaf Farasat
NPI 1255696407
$8,058.86
in general payments reported to CMS, 2019-2025
37 companies · $3,395 in 2025
The $3,395 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $106 · 2021: $272 · 2022: $669 · 2023: $792 · 2024: $2,826 · 2025: $3,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,612 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,612.37 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,542.72 | 2020-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $714.25 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $558.89 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Dexcom, INC. | $526.28 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $503.69 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.16 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Cequr Corporation | $403.76 | 2024-2025 | Cequr Simplicity |
| Senseonics, Incorporated | $400.00 | 2024 | Eversense |
| Ascensia Diabetes Care US INC. | $332.76 | 2023-2025 | |
| Novo Nordisk INC | $323.13 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $299.90 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $277.26 | 2023-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $219.31 | 2024-2025 | Isturisa, Signifor Lar |
| Bayer Healthcare Pharmaceuticals INC. | $186.25 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $174.03 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $128.81 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $123.45 | 2021-2022 | |
| Medtronic, INC. | $121.60 | 2024-2025 | Minimed 780g |
| Horizon Therapeutics Plc | $112.49 | 2023 | Tepezza |
| Abbvie INC. | $77.34 | 2021-2024 | |
| Ascendis Pharma Endocrinology INC | $62.30 | 2025 | Yorvipath |
| Corcept Therapeutics | $60.83 | 2025 | Korlym |
| Harmony Biosciences LLC | $48.17 | 2025 | |
| Sequel Med Tech, LLC | $47.72 | 2025 | Twiist |
| Boston Scientific Corporation | $47.65 | 2025 | General - Pain Management |
| Madrigal Pharmaceuticals | $46.05 | 2025 | Rezdiffra |
| Allergan, INC. | $45.09 | 2020 | |
| Beta Bionics, INC. | $31.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Kyowa Kirin, INC. | $25.40 | 2025 | |
| Neurocrine Biosciences, INC. | $25.21 | 2025 | |
| Alexion Pharmaceuticals, INC. | $25.03 | 2024 | Strensiq |
| Lantheus Medical Imaging, INC. | $23.33 | 2023 | Definity |
| Pfizer INC. | $23.06 | 2023 | |
| Novartis Pharmaceuticals Corporation | $21.91 | 2020 | |
| Mannkind Corporation | $21.38 | 2025 | |
| Vivus LLC | $19.65 | 2024 | Qsymia |
| Currax Pharmaceuticals LLC | $14.63 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sadaf Farasat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.